Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Cancer Causes Control. 2024 May;35(5):865-872. doi: 10.1007/s10552-023-01847-z. Epub 2024 Jan 27.
Although national medical organizations often neglect to include trans and gender diverse (TGD) people in their breast and cervical cancer screening recommendations, the World Profession Association of Transgender Health recommends that TGD people who are at risk for these cancers follow existing guidelines for cisgender women. Despite WPATH's recommendations, TGD people are less likely to get screened in large part due to discrimination. The COVID-19 pandemic has limited access to cancer screenings among cisgender people, but it is unknown how this has impacted TGD people.
Using national survey data from the Behavioral Risk Factors Surveillance System (BRFSS), we examined differences in cervical and breast cancer screening noncompliance across gender identity at two time points: before and during the COVID-19 pandemic.
Screening noncompliance increased during the COVID-19 pandemic among cisgender and TGD people (e.g., transgender men, gender non-conforming people). Compared to cisgender women, transgender men and gender non-conforming respondents had higher odds of breast cancer screening noncompliance before and during COVID-19. Transgender men had lower odds of cervical cancer screening noncompliance than cisgender women before COVID-19, but higher odds during the pandemic. Gender non-conforming respondents also had lower odds of cervical cancer screening noncompliance during COVID-19 compared to cisgender women.
Screening noncompliance for breast and cervical cancer was more common among TGD people than cisgender women; while these disparities existed before the COVID-19 pandemic, they were exacerbated during the pandemic. Future work should move beyond descriptive statistics and elucidate underlying causes to inform interventions.
尽管国家医疗组织在其乳腺癌和宫颈癌筛查建议中经常忽略跨性别和性别多样化(TGD)人群,但世界跨性别健康专业协会建议,有患这些癌症风险的 TGD 人群应遵循针对顺性别女性的现有指南。尽管 WPATH 提出了这些建议,但 TGD 人群接受筛查的可能性较低,部分原因是受到歧视。COVID-19 大流行限制了顺性别人群接受癌症筛查的机会,但尚不清楚这对 TGD 人群有何影响。
我们使用来自行为风险因素监测系统(BRFSS)的全国性调查数据,在两个时间点(COVID-19 大流行之前和期间),根据性别认同,检查了宫颈癌和乳腺癌筛查不依从的差异。
COVID-19 大流行期间,顺性别和 TGD 人群(例如跨性别男性、性别不一致的人)的筛查不依从率增加。与顺性别女性相比,在 COVID-19 大流行之前和期间,跨性别男性和性别不一致的受访者乳腺癌筛查不依从的可能性更高。在 COVID-19 之前,与顺性别女性相比,跨性别男性宫颈癌筛查不依从的可能性较低,但在大流行期间则较高。与顺性别女性相比,在 COVID-19 期间,性别不一致的受访者宫颈癌筛查不依从的可能性也较低。
TGD 人群的乳腺癌和宫颈癌筛查不依从率高于顺性别女性;尽管这些差异在 COVID-19 大流行之前就存在,但在大流行期间有所加剧。未来的工作应该超越描述性统计,阐明潜在原因,为干预措施提供信息。